111 related articles for article (PubMed ID: 15350604)
1. Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes.
Barbier O; Fontaine C; Fruchart JC; Staels B
Trends Endocrinol Metab; 2004 Sep; 15(7):324-30. PubMed ID: 15350604
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor alpha plays a vital role in inducing a detoxification system against plant compounds with crosstalk with other xenobiotic nuclear receptors.
Motojima K; Hirai T
FEBS J; 2006 Jan; 273(2):292-300. PubMed ID: 16403017
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
Miyachi H
IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
[TBL] [Abstract][Full Text] [Related]
4. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
[TBL] [Abstract][Full Text] [Related]
6. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Carcinogenesis; 2005 Jan; 26(1):219-27. PubMed ID: 15447978
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha.
Kane CD; Francone OL; Stevens KA
Gene; 2006 Oct; 380(2):84-94. PubMed ID: 16828988
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Grau R; Punzón C; Fresno M; Iñiguez MA
Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide analysis of PPARalpha activation in murine small intestine.
Bünger M; van den Bosch HM; van der Meijde J; Kersten S; Hooiveld GJ; Müller M
Physiol Genomics; 2007 Jul; 30(2):192-204. PubMed ID: 17426115
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.
González MC; Corton JC; Cattley RC; Herrera E; Bocos C
Biochimie; 2009 Aug; 91(8):1029-35. PubMed ID: 19497347
[TBL] [Abstract][Full Text] [Related]
12. Hypolipidemia induced by PPARalpha agonists: HNF-4alpha as an alternative to PPARalpha.
Bar-Tana J
Curr Opin Investig Drugs; 2004 Sep; 5(9):941-6. PubMed ID: 15503648
[TBL] [Abstract][Full Text] [Related]
13. Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C.
Gray JP; Burns KA; Leas TL; Perdew GH; Vanden Heuvel JP
Biochemistry; 2005 Aug; 44(30):10313-21. PubMed ID: 16042408
[TBL] [Abstract][Full Text] [Related]
14. PPARalpha activators may be good candidates as antiaging agents.
Erol A
Med Hypotheses; 2005; 65(1):35-8. PubMed ID: 15893114
[TBL] [Abstract][Full Text] [Related]
15. Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro.
Richert L; Tuschl G; Viollon-Abadie C; Blanchard N; Bonet A; Heyd B; Halkic N; Wimmer E; Dolgos H; Mueller SO
Drug Metab Dispos; 2008 Apr; 36(4):702-14. PubMed ID: 18216275
[TBL] [Abstract][Full Text] [Related]
16. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
17. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.
Oishi K; Uchida D; Ishida N
FEBS Lett; 2008 Oct; 582(25-26):3639-42. PubMed ID: 18840432
[TBL] [Abstract][Full Text] [Related]
18. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes.
Mazzucotelli A; Viguerie N; Tiraby C; Annicotte JS; Mairal A; Klimcakova E; Lepin E; Delmar P; Dejean S; Tavernier G; Lefort C; Hidalgo J; Pineau T; Fajas L; Clément K; Langin D
Diabetes; 2007 Oct; 56(10):2467-75. PubMed ID: 17646210
[TBL] [Abstract][Full Text] [Related]
19. Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha.
Shimakura J; Terada T; Saito H; Katsura T; Inui K
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G851-6. PubMed ID: 16751172
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells.
Nagasawa M; Akasaka Y; Ide T; Hara T; Kobayashi N; Utsumi M; Murakami K
Biochem Pharmacol; 2007 Dec; 74(12):1738-46. PubMed ID: 17904533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
